Hepatic Artery Infusion Background

The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.

Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.

Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.

The FDA has issued a CRL to LNTH-2501 for the localization of SSTR-positive NETs.

The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.

China’s NMPA has satri-cel for pretreated, CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma.